Based on degree ordering, the top seven proteins—glyceraldehyde-3-phosphate dehydrogenase (GAPDH), tumor necrosis factor (TNF), glycogen synthase kinase-3 beta (GSK3B), G1/S-specific cyclin-D1 (CCND1), myeloid cell leukemia-1 (MCL1), interleukin-2 (IL2), and cyclin-dependent kinase 2 (CDK2)—were identified as the core protein targets, which may be key targets for esculin in the treatment of RCC (Figure 1D). This evidence concerns the gene CDK2 and renal cell carcinoma.